NEW YORK--(BUSINESS WIRE)--The Law Offices of Vincent Wong notifies investors of an investigation concerning whether Dr. Reddy’s Laboratories Ltd. (“Dr. Reddy’s”) (NYSE:RDY) violated federal securities laws.
Click here to learn about the case: http://docs.wongesq.com/RDY-Info-Request-Form-1688. There is no cost or obligation to you.
On November 6, 2015, Dr. Reddy’s announced that it had received a warning letter issued by the U.S. Food and Drug Administration concerning inadequate quality control standards at three of Dr. Reddy’s manufacturing plants in India. Then on August 10, 2017, Dr. Reddy’s disclosed that the Regierung von Oberbayern (the district government of Upper Bavaria) did not renew the good manufacturing practices compliance certificate of a manufacturing unit of Dr. Reddy’s German subsidiary Betapharm Arzneimittel, located in India. Following this news, shares of Dr. Reddy’s stock was down more than 5% on intraday trading on August 10, 2017.
To learn more about the investigation of Dr. Reddy’s contact Vincent Wong, Esq. either via email email@example.com, by telephone at 212.425.1140, or visit http://docs.wongesq.com/RDY-Info-Request-Form-1688.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.